132 results
8-K
EX-99.1
ZNTL
Zentalis Pharmaceuticals Inc
3 Jun 24
Regulation FD Disclosure
7:00am
, resulting in mitotic catastrophe and cell death CDKs and their cyclin binding partners promote progression through the cell cycle Following DNA … Checkpoint DNA damage accumulates Cancer Cell Mitotic Catastrophe and Death DNA damage P CDK2 Active/Not phosphorylated CDKCyclin CDKCyclin
DEFA14A
ZNTL
Zentalis Pharmaceuticals Inc
29 May 24
Additional proxy soliciting materials
7:16am
and qualification of his successor and his earlier death, resignation or removal. Dr. Walker has also been appointed to serve on the Audit Committee of the Board
8-K
ZNTL
Zentalis Pharmaceuticals Inc
29 May 24
Departure of Directors or Certain Officers
7:04am
of Stockholders, subject to the election and qualification of his successor and his earlier death, resignation or removal. Dr. Walker has also been
8-K
EX-99.1
ZNTL
Zentalis Pharmaceuticals Inc
7 May 24
Zentalis Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Progress
7:03am
and leading to mitotic catastrophe and cancer cell death.
About Zentalis Pharmaceuticals
Zentalis® Pharmaceuticals, Inc. is a clinical-stage
8-K
EX-99.1
zcnqnxto4sg31a2d22bj
9 Apr 24
Regulation FD Disclosure
4:30pm
8-K
EX-99.1
7diniud8ka79vo7q 35
27 Feb 24
Zentalis Pharmaceuticals Reports Full Year 2023 Financial Results and Operational Updates
7:04am
8-K
EX-3.1
tzrlvb 8chnono
15 Feb 24
Amendments to Articles of Incorporation or Bylaws
4:12pm
8-K
EX-99.1
bt4x1v
6 Nov 23
Zentalis Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Updates
9:04am
8-K
EX-99.2
mtnbl3ukt
6 Nov 23
Zentalis Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Updates
9:04am